Usefulness and safety of percutaneous myocardial laser revascularization for refractory angina pectoris

Salem, Mohammed; Rotevatn, Svein; Stavnes, Sindre; Brekke, Magne; Vollset, Stein Emil; Nordrehaug, Jan Erik

doi:10.1016/j.amjcard.2004.01.032

Cited by 52 publications

(66 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also reported that LV function may be compromised immediately after the procedure [51]. Five randomized clinical trials involving over 1,000 patients have since examined the safety and efficacy of percutaneous DMR, using the different available catheter systems, with mixed outcomes [6,[52][53][54][55]. Notably, the trials that were blinded failed to demonstrate any sustained treatment benefit [6,53,55].…”

Section: Direct Myocardial Laser Revascularizationmentioning

confidence: 97%

Endoventricular Electromechanical Mapping—The Diagnostic and Therapeutic Utility of the NOGA® XP Cardiac Navigation System

Psaltis

Worthley

2008

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

Combined analysis of the electrical and mechanical function of the heart holds promise as a means of acquiring a better understanding of a variety of cardiac diseases that ultimately may lead to heart failure. The NOGA XP Cardiac Navigation System is a unique, nonfluoroscopic, catheter-based technology that achieves real-time acquisition of three-dimensional, endoventricular electromechanical maps. Through the provision of point-by-point measurements of endocardial electrical activation and voltage and mechanical shortening, electromechanical mapping has been evaluated for its ability to identify regional myocardial ischemia and characterize tissue viability. A decade of preclinical and clinical research has verified its safety and feasibility and raised the possibility of its application as a diagnostic adjunct to conventional angiography in the catheterization laboratory. However, this role has not yet been realized outside of the research setting. Instead, a more prominent niche for NOGA XP has emerged as a therapeutic tool for guiding direct myocardial interventions, most notably the targeted administration of regenerative therapies (e.g., cells, genes) to the heart. In this review, we discuss the fundamental aspects of this electromechanical mapping system and the evidence for both its diagnostic and therapeutic utility.

show abstract

Section: Direct Myocardial Laser Revascularizationmentioning

confidence: 97%

Endoventricular Electromechanical Mapping—The Diagnostic and Therapeutic Utility of the NOGA® XP Cardiac Navigation System

Psaltis

Worthley

2008

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

show abstract

“…Also, in PACIFIC, diverse outcomes tended to be higher with laser therapy (924). Although the randomized, double-blind BELIEF trial (Blinded Evaluation of Laser PMR Intervention Electively For angina pectoris) of 82 patients appeared to show some benefit of percutaneous laser transmyocardial revascularization versus sham procedure on angina class and quality-of-life measures, the results were inconclusive given the small size of the study (925). To date, data are insufficient for FDA approval of percutaneous laser therapy.…”

Section: Society For Cardiovascular Angiography and Interventionsmentioning

confidence: 63%

ACC/AHA/SCAI Practice Guidelines, February 21, 2006

Wilkins¹

2006

Circulation

350

View full text Add to dashboard Cite

“…Clinical staff performing the intervention were screened from the patients’ view 54 either by a surgical drape 52 or by arranging the operating room in a way that the patient could not see the procedure 44 . In the trial by Stone and colleagues, patients were heavily sedated and wore opaque goggles 30 .…”

Section: Strategies Used To Maintain Blinding In Interventional Placementioning

confidence: 99%

Blinding in trials of interventional procedures is possible and worthwhile

2017

View full text Add to dashboard Cite

In this paper, we have used evidence from our earlier review of surgical randomised controlled trials with a placebo arm to show that blinding in trials of interventional procedures is feasible, and that many creative methods can be used to make the active and the placebo procedure as similar as possible. We give examples of ingenious strategies used to simulate the active procedure and make the placebo control indistinguishable from the active treatment. We discuss why it is important to blind of patients, assessors, and caregivers and the types of bias that may occur in interventional trials. Finally, we describe the benefits of blinding, from the obvious ones such as avoiding bias, as well as less evident benefits such as avoiding patient drop out in the control arm.

show abstract

Usefulness and safety of percutaneous myocardial laser revascularization for refractory angina pectoris

Cited by 52 publications

References 19 publications

Endoventricular Electromechanical Mapping—The Diagnostic and Therapeutic Utility of the NOGA® XP Cardiac Navigation System

Endoventricular Electromechanical Mapping—The Diagnostic and Therapeutic Utility of the NOGA® XP Cardiac Navigation System

ACC/AHA/SCAI Practice Guidelines, February 21, 2006

Blinding in trials of interventional procedures is possible and worthwhile

Contact Info

Product

Resources

About